EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudie

Semaglutide Versus Dulaglutide and Liraglutide in Chinese Patients With T2DM : A Multicenter Real‐World Study

Zeyu Xie iD, Bin Gan, Weiling Cao, Jiang Liu, Jisheng Chen

Obesity · 2026

DOI: 10.1002/oby.70065 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Obesity, 2026. Verfasst von Zeyu Xie und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Third Affiliated Hospital (The Affiliated Luohu Hospital) of Shenzhen University, Shenzhen, China. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Diabetes Mellitus, Type 2, Liraglutide, Recombinant Fusion Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Sanming Project of Medicine in Shenzen Municipality, the 2024 "Real-World Evidence and Health Technology Assessment for Clinical Use of Medicines" Special Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

We aimed to compare the effectiveness and safety of semaglutide 1.0 mg versus dulaglutide 1.5 mg and liraglutide 1.8 mg in patients with type 2 diabetes mellitus (T2DM) under routine clinical care.

Methods

This multicenter, retrospective, real‐world study enrolled Chinese adults with T2DM who initiated GLP‐1 receptor agonist therapy in endocrinology clinics between January 1, 2022, and August 31, 2024. We compared the effectiveness of these agents on HbA1c and weight loss, with safety as a key exploratory endpoint. Additionally, the UK Prospective Diabetes Study Outcomes Model 2.1 was utilized to project long‐term health outcomes.

Results

This multicenter retrospective study included 111, 74, and 107 patients treated with semaglutide 1.0 mg, dulaglutide 1.5 mg, and liraglutide 1.8 mg, respectively. After 1:1 propensity score matching, semaglutide demonstrated significantly greater HbA1c reduction compared to both dulaglutide (−0.27% ± 0.70%, p = 0.008) and liraglutide (−0.39% ± 0.87%, p < 0.001), along with higher glycemic target achievement rates. Semaglutide was associated with improved outcomes in all death, cardiovascular death, and other death endpoints. No significant differences in safety profiles were observed among the three treatment groups.

Conclusions

Semaglutide demonstrated superior glycemic control and weight loss compared to both dulaglutide and liraglutide, whereas dulaglutide and liraglutide exhibited comparable clinical efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like PeptidesDiabetes Mellitus, Type 2LiraglutideRecombinant Fusion ProteinsHypoglycemic AgentsImmunoglobulin Fc FragmentsHumansMaleFemaleMiddle AgedRetrospective StudiesGlycated HemoglobinAgedChinaTreatment OutcomeGlucagon-Like Peptide-1 Receptor AgonistsWeight LossBlood GlucoseAdultGlucagon-Like Peptide 1SemaglutideEast Asian People

Stichwörter der Autor:innen

GLP‐1 receptor agonistseffectivenessobservationalreal‐worldsafetysemaglutide

Substanzen

Glucagon-Like PeptidesLiraglutideRecombinant Fusion ProteinsHypoglycemic AgentsGlycated HemoglobinImmunoglobulin Fc FragmentsGlucagon-Like Peptide-1 Receptor AgonistsBlood GlucoseGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Department of Pharmacy, The Third Affiliated Hospital (The Affiliated Luohu Hospital) of Shenzhen University, Shenzhen, China.
  • Department of Pharmacy, Shenzhen Baoan People's Hospital, Shenzhen, Guangdong, China.
  • Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China.

ORCID-Profile: Zeyu Xie

Förderung

  • Sanming Project of Medicine in Shenzen Municipality
  • the 2024 "Real-World Evidence and Health Technology Assessment for Clinical Use of Medicines" Special Project

Zitieren

APA

Xie, Z., Gan, B., Cao, W., Liu, J., & Chen, J. (2026). Semaglutide Versus Dulaglutide and Liraglutide in Chinese Patients With T2DM : A Multicenter Real‐World Study. Obesity. https://doi.org/10.1002/oby.70065

Vancouver

Xie Z, Gan B, Cao W, Liu J, Chen J. Semaglutide Versus Dulaglutide and Liraglutide in Chinese Patients With T2DM : A Multicenter Real‐World Study. Obesity. 2026. doi:10.1002/oby.70065

BibTeX
@article{Xie2026,
  author = {Xie, Zeyu and Gan, Bin and Cao, Weiling and Liu, Jiang and Chen, Jisheng},
  title = {Semaglutide Versus Dulaglutide and Liraglutide in Chinese Patients With T2DM : A Multicenter Real‐World Study},
  journal = {Obesity},
  year = {2026},
  doi = {10.1002/oby.70065}
}
Kostenlos starten →